Journal list menu
Export Citations
Download PDFs
ISSUE INFORMATION
Issue Information
- Pages: 907-911
- First Published: 17 October 2022

Cover Legend
The 26th Congress of the APSR (https://apsr2022.org/) will be held in Seoul, South Korea, 17–20 November 2022, hosted by the Korean Academy of Tuberculosis & Respiratory Diseases (KATRD). Photo credit: ‘Fireworks Festival in Seoul South Korea’ by kampon/ stock.adobe.com
EDITORIALS
Adding some NOVELTY to treatable traits
- Pages: 912-913
- First Published: 04 August 2022
See related article
Long-term trends of COPD mortality: Gaps and opportunities
- Pages: 914-915
- First Published: 02 August 2022
See related article
A clinical short-cut to identifying short telomeres in idiopathic pulmonary fibrosis?
- Pages: 916-917
- First Published: 28 August 2022
See related article
A paediatric bronchoscopist's ‘Field of Dreams’: Will the flexible cryoprobe hit a home run?
- Pages: 918-919
- First Published: 07 September 2022
See related article
COMMENTARIES
Targeting vasculature to reduce fetal growth restriction associated bronchopulmonary dysplasia
- Pages: 920-922
- First Published: 07 September 2022
Bronchiectasis: A pulmonary disease with systemic consequences
- Pages: 923-925
- First Published: 13 September 2022
Choosing and switching biological agents in severe asthma
- Pages: 926-928
- First Published: 26 September 2022
ORIGINAL ARTICLES
Asthma and Allergy
Treatable traits in the NOVELTY study
- Pages: 929-940
- First Published: 21 July 2022
This study shows which treatable traits are present and/or absent in patients diagnosed with ‘asthma’, ‘COPD’ (chronic obstructive pulmonary disease) and ‘asthma + COPD’ in a global, observational study of more than 11,000 patients (NOVELTY), and how their prevalence changes with disease severity.
See related Editorial
COPD
Chronic obstructive pulmonary disease (COPD) mortality trends worldwide: An update to 2019
- Pages: 941-950
- First Published: 13 July 2022

Global age-standardized mortality due to chronic obstructive pulmonary disease (COPD), updated to 2019, reported a decrease in most countries for men, whilst a plateauing or a slight increase for women, although heterogeneity by world region was observed. COPD still remains a leading cause of death and disability, in particular in countries with lower socio-demographic index (SDI).
See related Editorial
Environmental and Occupational Lung Disease
PM2.5 exposure and risk of lung adenocarcinoma in women of Taiwan: A case–control study with density sampling
- Pages: 951-958
- First Published: 24 June 2022

While the prevalence of smoking among Taiwanese women is <5%, lung cancer incidence remains high. We used long-term data considering residential changes since 2000, and allowed 5–10 years of latency. PM2.5 (fine particulate matter with an aerodynamic diameter of ≤2.5 μm) exposure over 30 μg/m3 was associated with an increased risk of lung adenocarcinoma in 15,943 women.
Interstitial Lung Disease
Extrapulmonary manifestations of a telomere syndrome in patients with idiopathic pulmonary fibrosis are associated with decreased survival
- Pages: 959-965
- First Published: 13 April 2022
Clinical features suggestive of a telomere syndrome are present in a quarter of patients with idiopathic pulmonary fibrosis. These features include a history or family history of haematological or liver disease, or haematological laboratory abnormalities. They are associated with lower leukocyte telomere length and are independently associated with decreased survival.
See related Editorial
Interventional Pulmonology
Cryotherapy in the paediatric airway: Indications, success and safety
- Pages: 966-974
- First Published: 28 August 2022
This largest case collection of cryotherapy procedures in the paediatric airway to date demonstrates that cryotherapy can be safely and successfully applied for cryobiopsy, restoration of airway patency and foreign body removal. Paediatric interventional bronchoscopists are encouraged to add cryotherapy to their armamentarium of airway interventions in the paediatric airway.
See related Editorial
Sleep and Ventilation
Atomoxetine and fesoterodine combination improves obstructive sleep apnoea severity in patients with milder upper airway collapsibility
- Pages: 975-982
- First Published: 10 July 2022
We studied the combination of atomoxetine and fesoterodine (Ato-Feso), an extended-release anti-muscarinic, on obstructive sleep apnoea (OSA) severity and endotypes. Despite the absence of an effect on OSA severity, Ato-Feso led to improvements in OSA profile, reducing apnoea index and overnight hypoxaemia, especially in patients characterized by low-to-moderate pharyngeal collapsibility.
FORUM AND DEBATE
Scientific Letters
Dual bronchodilator treatment for prevention of COPD in at-risk smokers
- Pages: 983-986
- First Published: 11 September 2022
Predictors and outcomes of respiratory bacterial coinfections in patients with COVID-19 admitted to hospital: An observational prospective study
- Pages: 987-990
- First Published: 16 September 2022
LETTERS FROM ASIA-PACIFIC AND BEYOND
Leading women in respiratory medicine and research: Opportunities for international societies to support women with examples from the American Thoracic Society
- Pages: 991-993
- First Published: 19 September 2022

Special Series: Leading Women in Respiratory Medicine
Series Editors: Natasha Smallwood and Fanny Wai San Ko
See related editorial